-
Published30/05/2025
-
Today17/06/2025
-
Deadline10/11/2026
Utilities
- indicates text translated automatically in your browsing language
Conclusion of non-exclusive discount agreements pursuant to Section 130a(8) SGB V from 01.07.2025 Text automatically translated in your browsing language Automatically translated
Paragraph 130a(8) of the SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude framework discount contracts for the medicinal products to be dispensed at the expense of the statutory KK. GWQ acts as a company for efficiency and quality at KK in accordance with Section 130a(8) sentence 5 SGBV for its shareholder and customer funds. With regard to the relevant legal regulations for the award of public contracts, a regular process of drug-related, formal procurement procedures according to the regulations of the 4th part of the GWB by GWQ ServicePlus AG takes place. Until the entry into force of new drug discount agreements, GWQ would like to conclude drug discount agreements with all interested pharmaceutical companies. The contract starts on 01.07.2025. Text automatically translated in your browsing language Automatically translated
sen-info
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.